title: Cisplatin-treated murine peritoneal macrophages induce apoptosis in L929 cells: role of Fas-Fas ligand and tumor necrosis factor-tumor necrosis factor receptor 1.
abstract: Cisplatin [cis-diamminedichloroplatinum (II)]-treated murine peritoneal macrophages interact with L929 cells in vitro in a sequential manner, resulting in the formation of contact between the two cells. This interaction leads to the death of L929 cells by the process of apoptosis. The detailed investigations have suggested the involvement of two different pathways in macrophage-mediated L929 cell apoptosis. It is observed that the induction of apoptosis in L929 cells by cisplatin-treated macrophages is contact dependent and is mediated through Fas-Fas ligand and tumor necrosis factor-tumor necrosis factor receptor 1 pathways. This conclusion was based on the Western blot and immunoprecipitation analysis of Fas-Fas ligand, tumor necrosis factor-tumor necrosis factor receptor 1, Fas-associated death domain and tumor necrosis factor receptor-associated death domain. The Fas-Fas ligand interaction between macrophages and L929 cells increased the expression of Fas-associated death domain, and tumor necrosis factor-tumor necrosis factor receptor 1 interaction between macrophages and L929 cells increased the expression of tumor necrosis factor receptor-associated death domain in L929 cells. The induction of apoptosis in L929 cells was investigated by DNA fragmentation, Annexin V staining and Western blot analysis of Bax, Bcl-2, Bid, cytochrome c, poly(ADP ribose) polymerase, CAD, caspase-8 and caspase-3.
authors.affiliation: School of Biotechnology, Banaras Hindu University, Varanasi 221005, India.
authors.forename: Puja
authors.initials: P
authors.lastname: Chauhan
authors.forename: Ajit
authors.initials: A
authors.lastname: Sodhi
authors.forename: Shikha
authors.initials: S
authors.lastname: Tarang
mesh_terms: D000818:Animals; D017304:Annexin A5 / Q000378:metabolism; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D053148:Caspase 3 / Q000378:metabolism; D053181:Caspase 8 / Q000378:metabolism; D002460:Cell Line; D045744:Cell Line, Tumor; D002469:Cell Separation; D002945:Cisplatin / Q000494:pharmacology*; D018920:Coculture Techniques; D053938:DNA Fragmentation / Q000187:drug effects; D053222:Fas Ligand Protein / Q000502:physiology*; D005260:Female; D015151:Immunoblotting; D047468:Immunoprecipitation; D017737:Macrophages, Peritoneal / Q000187:drug effects*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008856:Microscopy, Fluorescence; D009363:Neoplasm Proteins / Q000096:biosynthesis; D047888:Receptors, Tumor Necrosis Factor, Type I / Q000187:drug effects / Q000502:physiology*; D048069:Tumor Necrosis Factors / Q000502:physiology*; D019014:fas Receptor / Q000502:physiology*
chemical_list: D017304:Annexin A5; D000970:Antineoplastic Agents; D053222:Fas Ligand Protein; D009363:Neoplasm Proteins; D047888:Receptors, Tumor Necrosis Factor, Type I; D048069:Tumor Necrosis Factors; D019014:fas Receptor; D053148:Caspase 3; D053181:Caspase 8; D002945:Cisplatin